EyePoint EYPT
NASDAQ EYPT
$4.58 +0.01 (+0.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

EyePoint (EYPT) Cash from Investing Activities (2010 - 2026)

EyePoint (EYPT) posted Cash from Investing Activities of $59.1 million for Q1 2026, up 179.09% sequentially from -$74.7 million in Q4 2025, and up 49.41% YoY from $39.5 million in Q1 2025.

Analysis

EyePoint (EYPT) Cash from Investing Activities (2010 - 2026) Analysis & Trends

EyePoint has reported Cash from Investing Activities for 17 years, with the latest figure at $59.1 million in Q1 2026.

  • Quarterly Cash from Investing Activities rose 49.41% year-over-year to $59.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.1 million (up 143.91% YoY) and the FY2025 annual result came in at $68.6 million, up 131.26% from the prior year.
  • Cash from Investing Activities climbed to $59.1 million in Q1 2026 per EYPT's latest filing, from -$74.7 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $59.1 million in Q1 2026 and troughed at -$160.4 million in Q2 2024.
  • A 5-year average of -$6.6 million and a median of $13.5 million in 2023 frame the typical range for Cash from Investing Activities.
  • The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 112325.0% in 2023, then tumbled 1291.02% in 2024.
  • Over 5 years, Cash from Investing Activities stood at $32.9 million in 2022, then plunged by 243.23% to -$47.1 million in 2023, then tumbled by 103.53% to -$96.0 million in 2024, then grew by 22.19% to -$74.7 million in 2025, then jumped by 179.09% to $59.1 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered $59.1 million, -$74.7 million, and $55.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 EyePoint 398.53 Mn 218.06 Mn 507,000.00 75.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 75.10 Mn
Mar 31, 2026 59.05 Mn
Dec 31, 2025 -74.67 Mn
Sep 30, 2025 55.39 Mn
Jun 30, 2025 48.34 Mn
Mar 31, 2025 39.53 Mn
Dec 31, 2024 -95.96 Mn
Sep 30, 2024 16.20 Mn
Jun 30, 2024 -160.40 Mn
Mar 31, 2024 20.81 Mn
Dec 31, 2023 -47.15 Mn
Sep 30, 2023 -1.72 Mn
Jun 30, 2023 13.47 Mn
Mar 31, 2023 32.09 Mn
Dec 31, 2022 32.92 Mn
Sep 30, 2022 6.27 Mn
Jun 30, 2022 -12,000.00
Mar 31, 2022 -56.44 Mn
Dec 31, 2021 -32.97 Mn
Sep 30, 2021 -131,000.00